| Name | Title | Contact Details |
|---|
LaterPay makes it possible to buy digital content, ad-free experiences and make even the smallest contributions without having to pay for them right away. The user commits to paying later and gets immediate access to the desired content – without havin...
Cloud.com is a Cupertino, CA-based company in the Software and Internet sector.
Darknet data provider offering access to the worlds largest dataset of darknet and deep web content.
Newselas platform takes real and new content from trusted providers and turns it into learning materials that meet State standards. Sign up free today!
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.